HC Wainwright Reiterates Buy Rating for Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $6.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 334.78% from the stock’s previous close.

Dyadic International Price Performance

Shares of DYAI opened at $1.38 on Monday. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 1.29. The stock’s 50 day moving average is $1.75 and its two-hundred day moving average is $1.60. Dyadic International has a twelve month low of $1.19 and a twelve month high of $2.67. The firm has a market capitalization of $40.35 million, a PE ratio of -4.93 and a beta of 0.73.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter. The business had revenue of $0.33 million during the quarter. Dyadic International had a negative net margin of 347.92% and a negative return on equity of 116.14%. During the same quarter in the previous year, the business posted ($0.03) EPS. Research analysts anticipate that Dyadic International will post -0.25 earnings per share for the current year.

Hedge Funds Weigh In On Dyadic International

An institutional investor recently bought a new position in Dyadic International stock. Callan Capital LLC bought a new stake in Dyadic International, Inc. (NASDAQ:DYAI) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 27,174 shares of the biotechnology company’s stock, valued at approximately $45,000. Callan Capital LLC owned approximately 0.09% of Dyadic International at the end of the most recent quarter. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.